CN107303330A - One kind prevents antipodagric Chinese medicine composition and preparation method and application - Google Patents
One kind prevents antipodagric Chinese medicine composition and preparation method and application Download PDFInfo
- Publication number
- CN107303330A CN107303330A CN201610247818.2A CN201610247818A CN107303330A CN 107303330 A CN107303330 A CN 107303330A CN 201610247818 A CN201610247818 A CN 201610247818A CN 107303330 A CN107303330 A CN 107303330A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- group
- gout
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Prevent antipodagric Chinese medicine composition and preparation method and application the invention discloses one kind.Chinese medicine composition of the present invention is made up of each Chinese medicine by following ratio of weight and number：20~40 parts of Desmodium styracifolium, 5~15 parts of giant knotweed, 5~15 parts of radix cyathulae, 10~30 parts of the dried rhizome of rehmannia, 3~9 parts of wide seed of cowherb shell, 5~15 parts of rhizoma atractylodis, 10~30 parts of plantain seed, 3~9 parts of golden cypress, 8~18 parts of the Radix Astragali, 5~15 parts of caulis trachelospermi, 5~15 parts of rhizoma cibotii.The present invention can be with preventing and treating gout.
Description
Technical field
The present invention relates to Chinese medical extract technical field, and in particular to one kind prevent antipodagric Chinese medicine composition and preparation method thereof and
Using.
Background technology
Gout (gout) is a kind of crystal-induced arthritis that purine metabolic disturbance and/or underexcretion are triggered, clinical table
It is now the acute and chronic arthritis of characteristic caused by hyperuricemia (hyperuricemia) and urate crystal deposition.Tophus
Except joint, tendon and its around deposit in addition to, can also be in renal deposition, and can occur urate nephropathy, uric acid lithangiuria
Deng severe patient can go out renal insufficiency.The clinical treatment of gout is based on chemical drugs, such as colchicin (colchicine), non-steroid
AID (NSAIDs), glucocorticoid, Allopurinol (allopurinol) etc..
The traditional Chinese medical science thinks that the cause of disease of gout is due to overfeeding delicious food, excessive drinking, overwork, the nervous or heresy such as damp and hot that is affected by the cold, and causes gas
Blood stagnation, blockage of phlegm and blood stasis, joint is fallen ill through flow of QI being obstructed.Differentiation of symptoms and signs for classification of syndrome includes：(1) beriberoid pyretic arthralgia symptom：Toes joint is red
Swollen heat pain, or wandering pain, or have heating, sweating, dysphoria with smothery sensation, pharyngalgia.Red tongue with thin fur, wiry and frequent pulse；(2) wind-cold-dampness arthralgia symptom：
Toes joint crymodynia and swell, meet that cold benefit is acute, obtaining Wen Ze subtracts, and local skin is micro- red or not red.Pink tongue, tongue is thin, stringy and tense pulse；
(3) the chronic combined symptoms shape of phlegm-blood stasis：Joint sting, night aggravation, breaking-out is frequent, with tubercle, joint deformity swelling, limitation of activity.
Tongue is dim red, or has ecchymosis, arteries and veins thin string or puckery；(4) insufficiency of both the spleen and the kindey symptom：Pale complexion, hands and feet being not warm, waist secret anguish, leg acid
It is soft, meet labor more very, it is sleeping then mitigate, night pollakiuria, lack gas powerless.Pale tongue, tongue is thin white, deep thready pulse.The Chinese traditional treatment of gout
Based on being treated with clinical syndrome differentiation, Chinese patent drug is fewer, mainly there is TONGFENGDING capsule, gout relaxing tablet etc..
The content of the invention
The purpose of the present invention aims to provide a kind of anti-antipodagric Chinese medicine composition and its preparation method and application.
Specifically, the first aspect of the present invention there is provided a kind of anti-antipodagric Chinese medicine composition, and it is matched somebody with somebody with following weight
The Chinese medicine material of ratio is made：
20~40 parts of Desmodium styracifolium, 5~15 parts of giant knotweed, 5~15 parts of radix cyathulae, 10~30 parts of the dried rhizome of rehmannia, wide seed of cowherb shell 3~9
Part, 5~15 parts of rhizoma atractylodis, 10~30 parts of plantain seed, 3~9 parts of golden cypress, 8~18 parts of the Radix Astragali, 5~15 parts of caulis trachelospermi, rhizoma cibotii 5~15
Part.
In a preference, the weight proportion of the Chinese medicine material is：
30 parts of Desmodium styracifolium, 9 parts of giant knotweed, 9 parts of radix cyathulae, 20 parts of the dried rhizome of rehmannia, 6 parts of wide seed of cowherb shell, 9 parts of rhizoma atractylodis,
20 parts of plantain seed, 6 parts of golden cypress, 12 parts of the Radix Astragali, 9 parts of caulis trachelospermi, 9 parts of rhizoma cibotii.
The second aspect of the present invention there is provided the preparation method of above-mentioned Chinese medicine composition, and it comprises the following steps：
Each bulk drug is taken to mix, decocting 2~3 times, add water 4~20 times of amounts every time, 1~3 hour every time, is by decocting liquid filtration merging
.
The application in preventing and treating the medicine or food of hyperuricemia is being prepared present invention also offers above-mentioned Chinese medicine composition.
The application in preventing and treating the medicine or food of urarthritis is being prepared present invention also offers above-mentioned Chinese medicine composition.
Present invention also offers application of the above-mentioned Chinese medicine composition in the medicine or food with analgesic activity is prepared.
The details of various aspects of the present invention will be able to detailed description in subsequent chapters and sections.By hereafter and claim description,
The features of the present invention, purpose and advantage will become apparent from.
Embodiment
The cause of disease of gout is due to overfeeding delicious food, excessive drinking, overwork, the nervous or heresy such as damp and hot that is affected by the cold, and causes qi and blood stagnation, phlegm
Stasis of blood numbness is hindered, and joint is fallen ill through flow of QI being obstructed.Desmodium styracifolium clearing heat and promoting diuresis in side, inducing diuresis for treating strangurtia, Return liver, kidney, bladder warp are drawn
Lead delicious food damp and hot from lower and go out, radix cyathulae dispelling stasis of blood and stimulating the menstrual flow, easing joint movement, the two is monarch drug in a prescription altogether, altogether the side's of presenting a memorial to the emperor clearing heat and promoting diuresis, by
The effect of blood stasis and smoothing collaterals；Wide seed of cowherb shell is promoting blood circulation and removing obstruction in channels, and dispersing swelling and dissipating binds, giant knotweed clearing heat and promoting diuresis, blood stasis removing analgesic can help radix cyathulae
Remove obstruction in channels to relieve pain, golden cypress heat-clearing and damp-drying drug, purging intense heat, except steaming, plantain seed reducing fever and causing diuresis, excreting dampness antidiarrheal can help Desmodium styracifolium reducing fever and causing diuresis,
Increase uric acid excretion, four strengthen our dampness removing dredging collateral effect jointly, therefore are ministerial drug；Rhizoma atractylodis are drying damp and strengthening spleen, expelling wind and clearing away cold, can
Alleviate patient with gout numbness and ache of cold dampness, Radix Astragali QI invigorating Li Shui, eliminating toxic of subsiding a swelling, dried rhizome of rehmannia nourishing yin and nourishing blood, by blood eliminating impediment, rhizoma cibotii wind-damp dispelling,
Filling liver kidney, strong waist and knee, three's tonifying Qi enriching yin, the strong kidney of blood-nourishing can both exempt the monarch and his subjects' clearing heat and promoting diuresis and exaggerate the anxiety of impairment of yin, can mend again
Liver kidney and except numbness pain, number tastes are adjutant altogether；Caulis trachelospermi is removed obstruction in channels to relieve pain, clearing heat for detumescence, draws all medicine dredging collateral and behavior makes medicine.All medicines
Share, altogether the side's of presenting a memorial to the emperor clearing heat and promoting diuresis, by blood stasis and smoothing collaterals, kidney tonifying eliminating impediment the effect of.
The Chinese medicine composition of the present invention can be used alone, or various mouths are made by the conventional method addition appropriate amount of auxiliary materials of this area
Formulation such as soft extract, tablet, oral liquid etc..
The Chinese medicine composition of the present invention can be prepared via a method which, that is, take each bulk drug to mix, and decocting 2~3 times adds water every time
4~20 times of amounts, 1~3 hour every time, decocting liquid filtration merging are produced.Also appropriate amount of auxiliary materials can be added, according to a conventional method further
Various formulations are made, include but is not limited to：The preparations such as granule, capsule, tablet.It can also be added in decocting liquid conventional auxiliary
Oral administration solution or paste etc. is made after material concentration.In addition to medicament is made, it can also be added in the Chinese medicine composition of the present invention
The various food additives such as various raw-food materials and antioxidant, pigment, enzyme preparation, are made by the conventional method of this area
Health food.
The details of various aspects of the present invention will be able to detailed description in subsequent chapters and sections.By hereafter and claim description,
The features of the present invention, purpose and advantage will become apparent from.
With reference to specific embodiment, the present invention is expanded on further.It should be understood that these embodiments be merely to illustrate the present invention without
For limiting the scope of the present invention.The experimental method of unreceipted actual conditions in the following example, generally according to normal condition or is pressed
According to the condition proposed by manufacturer.Unless otherwise indicated, otherwise all percentage, ratio, ratio or number be by weight
Meter.
Unless otherwise defined, all specialties used in text are identical with meaning known to one skilled in the art with scientific words.
In addition, any method similar or impartial to described content and material all can be applied in the inventive method.Described in text compared with
Good implementation only presents a demonstration with material to be used.
The features described above that the present invention is mentioned, or the feature that embodiment is mentioned can be in any combination.Disclosed in patent specification
All features can be used in combination with any combinations thing form, each feature disclosed in specification can provide phase with any
The alternative characteristics substitution of same, impartial or similar purpose.Therefore except there is a special instruction, disclosed feature be only it is impartial or
The general example of similar features.
Embodiment 1
Weigh medicinal material：It is Desmodium styracifolium 30kg, giant knotweed 9kg, radix cyathulae 9kg, dried rhizome of rehmannia 20kg, wide seed of cowherb shell 6kg, grey
Art 9kg, plantain seed 20kg, golden cypress 6kg, Radix Astragali 12kg, caulis trachelospermi 9kg, rhizoma cibotii 9kg, add water to cook 3 times, first
It is secondary to add water 1400 liters, decoct 2 hours, add water for the second time 1100 liters, decoct 1 hour, add water for the third time 1100 liters,
Decoct 1 hour, collecting decoction is concentrated into relative density 1.1 or so, spray drying obtains extract powder 32.5kg.
Embodiment 2
Weigh medicinal material：Desmodium styracifolium 20kg, giant knotweed 15kg, radix cyathulae 15kg, dried rhizome of rehmannia 10kg, wide seed of cowherb shell 3kg,
Rhizoma atractylodis 5kg, plantain seed 30kg, golden cypress 9kg, Radix Astragali 8kg, caulis trachelospermi 15kg, rhizoma cibotii 15kg, are added water to cook 2 times, the
Once add water 2900 liters, decoct 2 hours, add water for the second time 580 liters, decoct 1 hour, decocting liquid merges, add honeybee
Sweet 50kg, is concentrated into relative density 1.2~1.4 or so, soft extract is made.
Embodiment 3
Weigh medicinal material：It is Desmodium styracifolium 40kg, giant knotweed 5kg, radix cyathulae 5kg, dried rhizome of rehmannia 30kg, wide seed of cowherb shell 9kg, grey
Art 15kg, plantain seed 10kg, golden cypress 3kg, Radix Astragali 8kg, caulis trachelospermi 5kg, rhizoma cibotii 5kg, add water to cook 2 times, first
It is secondary to add water 2000 liters, decoct 3 hours, add water for the second time 1000 liters, decoct 1 hour, decocting liquid merges, be concentrated and dried,
Fine powder is ground into, lactose 8kg is added, mixed, tabletted 100000.
Embodiment 4
Weigh medicinal material：It is Desmodium styracifolium 27kg, giant knotweed 9kg, radix cyathulae 9kg, dried rhizome of rehmannia 21kg, wide seed of cowherb shell 9kg, grey
Art 9kg, plantain seed 21kg, golden cypress 6kg, Radix Astragali 12kg, caulis trachelospermi 9kg, rhizoma cibotii 9kg, add water to cook 2 times, first
It is secondary to add water 1500 liters, decoct 2 hours, add water for the second time 900 liters, decoct 1 hour, decocting liquid merges, and is concentrated into relatively close
Degree 1.1 or so, filtering, the appropriate oral solution typical additives of addition, such as conventional flavouring of sucrose, stevioside, and
Oral administration solution 1000000ml is made in the conventional bacteriostatic agent such as p-hydroxybenzoate, sodium benzoate, potassium sorbate, high pressure steam sterilization.
Embodiment 5
Got it filled material by gout side's prescription consumption of the present invention, extract powder is prepared as described in Example 1, carry out pharmacodynamics examination
Test research.
1. drug action of the gout side to mouse hyperuricemia
1.1 test objective
Currently used in the animal model of hyperuricemia Therapy study, Oteracil Potassium is used as the chemical inducer for suppressing uric acid generation
The hyperuricemia model of foundation, it is sensitive easy, reproducible with its, it is generally used in the world.This research uses oxygen piperazine
Sour potassium sets up Studies on Animal Models of Hyperuricemic Mice as the chemical inducer for suppressing uric acid generation, to evaluate gout side to antihyperuricemic
The drug action of disease.
1.2 test material
Animal：
Male mice in kunming (KM mouse), purchased from Shanghai Slac Experimental Animal Co., Ltd., animal productiong licensing number：
SCXK (Shanghai) 2012-0002
Reagent：
Oteracil Potassium：sigma
Allopurinol tablet, the production of Chongqing Qingyang pharmaceutcal corporation, Ltd, 0.1g*100 pieces/box.
Febuxostat tablet, Canadian Takeda productions, 80mg*30 pieces/bottle.
Uric acid (URIC) kit：Beckman companies
Xanthine oxidase (XO) determines kit, and Bioengineering Research Institute is built up in Nanjing.
Instrument：
BECKMAN COULTER AU480 automatic clinical chemistry analyzers；
1.3 test method
Kunming mice, by body weight stochastic averagina be grouped, every group 12, set up blank control group, hyperuricemia model group, not
Purine alcohol positive drug group, febuxostat tablet positive drug group, the low middle high dose group in gout side.Allopurinol positive drug group is filled
Stomach gives allopurinol, and dosage is 15mgkg-1；Febuxostat positive drug group gives febuxostat tablet, and dosage is 10mgkg-1。
Each dosage experiments group gavage in gout side gives each sample, low dosage 2.5g/kg；Middle dosage 5g/kg；High dose 10g/kg.Remaining is each
Group gives distilled water, successive administration 7d.Record each group the weight of animals.Oteracil Potassium, agent is injected intraperitoneally in 0.5h before last dose
Measure as 300mgkg-1, blank control group is injected intraperitoneally 0.5% sodium carboxymethylcellulose (CMC-Na), plucks eyeball after 1.5h and adopt
Blood, blood specimen collection places about 1h after room temperature, treats blood solidification completely after 3 500rmin-1, centrifuge 10min under the conditions of 4 DEG C,
Serum Biochemical Analyzer (BECKMAN COULTER AU480) is taken to detect serum uric acid.It is quick take liver and in
It is homogenized in ice bath, xanthine oxidase (XO) level in kit measurement serum and liver.
1.4 result of the test
As shown in table 1, intraperitoneal injection Oteracil Potassium causes hyperuricemia model mice serum uric acid level compared to blank control group
Significantly improve, both, which compare, has pole significant (P<0.01), display modeling success.Positive drug allopurinol and Fei Bu
SU11248 can significantly reduce the uric acid of hyperuricemia mouse to the level of Normal group.The middle and high dosage group in gout side
Serum uric acid is reduced, is compared through statistical analysis with model group with notable (P<0.05) with pole significant difference (P<0.01).
Gout side's low dose group also has the trend of relatively low uric acid.The low middle high dose group in gout side can dose dependent reduction antihyperuricemic
The serum uric acid level of disease model mice.
Table 1：Influence of the gout side to hyperuricemia model mice serum uric acid
Note：Compared △ △ P with blank control<0.01；Compared * P ＜ 0.05, * * P ＜ 0.01 with model control group
Serum respectively to each group mouse and liver xanthine oxidase (XO) activity detect, as shown in table 2, compared to
Empty table control group, has been injected intraperitoneally after Oteracil Potassium, and 65.3% He is respectively increased in the serum and liver XO activity of model group mouse
65.5%, with pole significant difference (P<0.01).Positive drug allopurinol and Febuxostat are XO inhibitor, sun
Property medicine group mice serum and liver XO levels are down to normal level substantially.Each dosage group in gout side also shows internal suppression
The effect of XO activity, compared to model group, low middle high dose group reduces serum XO levels 9.8%, 15.0% and 23.2% respectively,
Reduce liver XO levels 8.0%, 11.2% and 18.9%.Middle high dose group shows significant difference.
Table 2：Influence of the gout side to serum xanthin oxydase (XO) and liver the XO activity of high lithemia model mice
Note：Compared △ △ P with blank control<0.01；Compared * P ＜ 0.05, * * P ＜ 0.01 with model control group
The antihyperuricemic disease mouse model induced by application Oteracil Potassium, have studied drug action of the gout side to hyperuricemia,
Experimental result confirms, gout can dose dependent reduction hyperuricemia mouse serum uric acid level, reduce serum and liver
Dirty xanthine oxidase activity.
2. drug action of the gout side to urarthritis rat model
2.1 experiment purpose
The patient of clinic about more than 90% can trigger acute and chronic urarthritis due to hyperuricemia, and its reason is serum uric acid
Level is higher than its saturated concentration, and chronic Monosodium urate crystallization deposition occurs in joint, induces urarthritis.
This experiment crystallizes acute pedal swelling model using rat Monosodium urate, investigates gout side swollen to rat paw caused by Monosodium urate
Swollen suppression, and the influence to relevant inflammatory factors and cell factor, to evaluate the antigout arthritis effect of gout side.
2.2 test material
Gout side's extract powder vacuum sealed package, 4 DEG C stored refrigerated.
Animal：SD rats, are provided by Shanghai SLAC Co., Ltds.Quality certification number：SCXK (Shanghai) 2012-0002.
Indomethacin：White pulvis, Sigma produces, lot number：26H0807.Indomethacin 75mg is weighed, mortar is put.Grind
Wear into after fine powder, plus 0.5%CMC is ground.It is transferred to graduated cylinder, plus 0.5%CMC to 22.48ml.Being made into concentration is
6.667mg/ml suspension is standby.
YLS-7B toes capacity measurers：Huaibei Zhenghua Biological Instrument Co., Ltd. produces.
2.3 test method
2.3.1 Monosodium urate crystallization and the preparation of uric acid sodium solution
194ml distilled water adds 6ml 1M NaOH, boils, plus 1g uric acid, and PH to 7.2 is adjusted with 1N HC1, and stirring is cooled down,
4 DEG C of refrigerators preserve 24h, remove supernatant, are blotted sediment moisture with filter paper, are put into 70 DEG C of drying boxes and dry 2h, take out, scrape
Powder, is put into pulverization in mortar, is sieved, bottled standby with aperture 250um metallic screen.Take 500mg Monosodium urates brilliant
Body adds 18ml physiological saline, then adds 2ml Tween 80s, and heating stirring is configured to 20ml uric acid sodium solutions.
2.3.2 Monosodium urate crystallization induces urarthritis rat model
60 male SD rats (240-260g) are divided into Normal group, model group, Indomethacin group (5mg/kg) and pain
Totally 6 groups, every group 10 of low middle high three dosage groups in wind side (1.25,2.5,5g/kg).Start gavage and give within 2 days before modeling
Tested material, one time a day.Model group, normal rats are with same volume pure water gavage.Experiment same day gavage gives tested material 1h
Inserted afterwards with No. 6 injection needles in tested rat right hind leg tibiotarsus joint dorsal part 45° angle direction before shin bone on the inside of tendon, will
0.2mL (25mg/mL) Monosodium urate crystallization (MSU) suspension injection ankle-joint chamber, causes acute gouty arthritis.Normally
Group rat replaces MSU suspensions with sterile saline.Rat body weight is recorded daily.
2.3.3 Articular swelling is measured
Each group rat 4h, 8h, 12h, 24h, 48h, 72h before modeling, after modeling test tested toes volume respectively.With
The difference for causing scorching front and rear toes volume is swelling rate, carries out group difference and compares.
Vn、VtRepresent respectively and cause scorching front and rear toes volumetric values
2.3.4 rat gait is classified：By the method observation rat gait of (1988) such as Coderre, 0 grade after modeling 24h：Normal row
Walk；1 grade：Slight to walk lamely, tested lower limb slightly have bending；2 grades：Moderate is walked lamely, and tested lower limb just touch ground；3 grades：Weight
Degree is walked lamely, and tested lower limb leave ground, and tripodia lands walking.
2.3.5 the measure of swollen tissue (ankle-joint) inflammatory factor, cell factor and peripheral pain mediums：After last dose 1h, water
Chloralization rat is closed, is quickly being cut above Rat Right ankle-joint at 0.5cm, is cutting off sufficient pawl.Weigh, filling 5mL
Skin is peelled off in the beaker of physiological saline, periarticular tissue is cut off, liquid and tissue are together moved into test tube, 10min is vibrated,
1h, 4500rpm centrifugation 5min are soaked, then 4 DEG C of centrifugations, take supernatant to be divided into two parts, -20 DEG C of preservations.For IL-1 β,
IL-6, IL-8, TNF-α and PGE2 ELISA are determined.
2.3.6 urarthritis rat closes the pathological observation of all soft tissues：Quickly the tested joint of rat and surrounding are removed after modeling 48h
Soft tissue, is weighed, and is fixed with 10% formalin, section, and the Pathologic changes of all soft tissues are closed in HE dyeing, observation.
2.4 result of the test
2.4.1 influence of the gout side to urarthritis gait and Articular swelling
Gait change of each group rat after modeling is observed, appearance activity subtracts after the injection Monosodium urate crystallization of model group rats ankle-joint chamber
Few, right hind is often lifted, bending, and tripodia lands walking.Compared with model group, gout side's high dose group and positive control drug
Indomethacin group rat gait is clearly better, and tested lower limb are shown as during modeling 48h and slightly have bending, slight to walk lamely.In gout side
Dosage group rat shows as moderate limping, and tested lower limb just touch ground.Gout side's low dose group rat gait, which has no, to be clearly better.
The body weight of each group animal, the preceding toes volume of administration are without marked difference.In terms of toes swelling rate, sterilizing life is subcutaneously injected in metapedes
Reason salt solution only makes toes volume occur micro change.Inject after MSU, rat toes continue swelling in 48h.48h is administered
When, volume increase about 35%.Gout side has the effect for suppressing toes swelling.The 24h of low dose group upon administration, toes
Swelling rate is significantly less than modeling group；Middle dose group is in the 8h of administration, and toes swelling rate is significantly less than modeling group；And high dose group
Toes swelling rate is significantly less than modeling group within all times of observation, and its effect is suitable with 8mg/kg Indomethacins.Gout side
Effect there is obvious dose-effect relationship.Positive drug Indomethacin also significantly inhibits toes swelling.It see the table below.
Table 3：Gout side causes the effect of rat toes swelling to MSU
*p<0.05；**p<0.01, compared with model group
2.4.2 influence of the gout side to inflammatory factor in swollen tissue and cell factor
As shown in table 4, compared with Normal group, the inflammation factor in model group rats joint and periarticular swollen tissue
It is bad with cell factor such as interleukin-1 ' beta ' (IL-1 β), interleukin-6 (IL-6), interleukin 8 (IL-8), tumour
Necrosis factor-α (TNF-α) and prostaglandin E2 (PGE2) level occur in that significantly rise (P<0.01).With model group phase
Than, gout can significantly reduce in urarthritis rat articular and periarticular swollen tissue the inflammatory factor of all measure and
Level (the P of cell factor<0.01 or P<0.05), and in dose-dependence.
In all tested materials, positive control drug Indomethacin reduction swollen tissue in IL-1 β and IL-6 ability be it is most strong,
The range of decrease is respectively 47.1% and 81.8%；But in reduction swollen tissue in terms of IL.8, TNF-α and PGE2, with high dose pain
The reduction amplitude of wind side is close, is not significantly different (P>0.05).This explanation gout side has good suppression acute gout
The ability of inflammatory factor and cell factor, right with the positive to a certain extent in rats with arthritis joint and periarticular swollen tissue
It is close according to medicine Indomethacin, show that it is active in terms of anti-inflammatory.
Table 4：Influence to inflammatory factor and cell factor in urarthritis rat articular and its surrounding swollen tissue
*p<0.05；**p<0.01, compared with model group
2.5 experiment brief summaries
To toes swelling caused by injection MSU at rat articular, urarthritis model is caused.Gout side have dosage according to
Rely property inhibitory action.Drug dose is bigger, and its action intensity is bigger, works faster, holds time longer.Gout side also can agent
Measure inflammatory factor and cell factor in the suppression urarthritis rat articular and periarticular swollen tissue of dependence.The above is real
Checking is real, and gout side has the drug action for suppressing gouty inflammation.
3. gout side's analgesic effect is studied
3.1 mouse hot-plate analgesic experiments
Hot plate method is the method for conventional screening antalgesic both at home and abroad, and the experiment, which is acted, is first to heat to 55 degree of hot plate analgetic apparatus.With
Kick, lick metapedes, jump etc. as the index of pain reaction.Metapedes is wherein licked often as a kind of acute uncomfortable abnormal movement,
Therefore the index that multiselect reacts as " pain ", antalgesic can be postponed substantially the time for licking metapedes.This experimental basis classics
Hot plate method in mice (is edited by Xu Shuyun《Pharmacological experimental methodology》The second edition (People's Health Publisher, 1991) is to medicine
Thing carries out the evaluation of analgesic effect.
3.1.1 materials and methods
Experimental animal：Kunming mouse (female, 18-22g), Chinese Academy of Sciences's Shanghai animal center is provided.
Hot plate analgetic apparatus：Zhejiang Ninghai Bai Shi electromedicines instrument plant produces, model GJ-8402.
Experimental method：
1) a certain amount of gout side is weighed, is completely dissolved in physiological saline, suitable concentration gout side solution is made into.Experiment is set pair
According to the high, medium and low dosage group of group and gout side (10g/kg, 5g/kg, 2.5g/kg), it is administered orally.
2) normal mouse is selected：Laboratory temperature is controlled at 22 degree or so, and pain threshold detector hot plate temperature is adjusted to 55 degree, records small
Mouse is surveyed 2 times altogether from hot plate is put into there is licking the metapedes time as the pain thresholding of the mouse, every minor tick 20 minutes, with average value
It was qualified mouse no more than 30 seconds.
3) experimental mice：Qualified mouse is grouped at random, every group 10.Subcutaneous administration.Each group upon administration 0.5h,
1.0h, 1.5h, 2.0h, 2.5h, 3.0h determine the mouse pain reaction time once, and record mouse is from hot plate is put into occurring licking metapedes
Time, thought that the medicine was effective more than 1 minute.
3.1.2 experimental result：
Table 5：The threshold of pain of gout side low dose group mouse
Table 6：The threshold of pain of gout side middle dose group mouse
Table 7：The threshold of pain of gout side high dose group mouse
It was found from result above, in gout side's low dose group in 12 mouse 2 have analgesic activity；In middle dose group in 12 mouse
7 have analgesic activity；In high dose group in 12 mouse 10 have analgesic activity.Gout side acted on peak at 1-1.5 hours, and 3 is small
When or so most of mouse recover normal.
Above experimental result confirms that there is analgesic activity gout side in hot-plate analgesia experiment.
3.2 mouse acetic acid twistings are tested
When many exogenous chemical substances touch complete skin and mucous membrane, pain can be caused.Therefore, by some chemistry
Stimulant is coated on the nerve endings or injection artery, vein or intraperitoneal of the skin bubble base portion exposure of opening, can cause pain mould
Type, is used as research pain physiology and the method for screening analgesic.Acetum is a kind of effective analgesia solution, by acetic acid
In solution injection intraperitoneal mouse, cause deep, large area and more lasting pain stimulation, cause small white mouse to produce " twisted "
Reaction (belly indent, trunk and back leg extension, hips up).Antalgesic has inhibitory action, can significantly reduce generation " askew
The small white mouse number of torsion " reaction.
3.2.1 materials and methods
Experimental animal：Kunming mouse 48, male and female half and half, by the Chinese Academy of Sciences, Experimental Animal Center is provided, and body weight is 18-20g.
Kunming mice is randomly divided into 4 groups, every group 12 on demand.
Experimental method：
A certain amount of gout side is weighed, is allowed to be completely dissolved in physiological saline, gout side's solution of suitable concn is made into.
Experiment sets the basic, normal, high dosage group of control group and gout side (2.5g/kg, 5g/kg, 10g/kg), and every group of mouse difference is oral
Gout side's solution of gavage physiological saline or various dose, 60min pneumoretroperitoneums give 0.6% glacial acetic acid solution (10ml/kg, ip),
Mouse writhing number of times in 15min is recorded, and by the analgesic potency of following equation calculating gout side.
Analgesic potency (%)=100% × (control group writhing number of times-administration group writhing number of times)/control group writhing number of times.
3.2.2 experimental result
In the experiment of mouse acetic acid twisting, gout side shows analgesic potency, and analgesic potency increases and increased with gout prescription amount.
When gout side's low dosage, analgesic potency is 31.15 ± 6.30%；When gout side's middle dosage, analgesic potency is 55.14 ± 2.75%；
When gout side's high dose, analgesic potency is 71.65 ± 2.88%.
Table 8：The analgesic potency that gout side is tested mouse writhing
3.3 research brief summaries
This experiment is carried out from classical mouse hot-plate analgesic model and mouse acetic acid twisting model to the analgesic activity of gout side
Correlative study, test result indicates that gout side be respectively 2/12 to the analgesia positive rate of hot-plate analgesia model in basic, normal, high dosage,
7/12、10/12；Analgesic potency to mouse acetic acid twisting model is respectively 31.15 ± 6.30%, 55.14 ± 2.75% and 71.65
± 2.88%.Above experimental result confirms that gout side has certain analgesic activity.
Many aspects involved in the present invention have been explained as above.However, it should be understood that without departing from spirit of the invention
Under the premise of, those skilled in the art can carry out equivalent change and modification to it, and the change and modification equally fall into this Shen
Please appended claims coverage.
Claims (6)
1. one kind prevents antipodagric Chinese medicine composition, it is characterised in that it is made of the Chinese medicine material of following weight proportion：
20~40 parts of Desmodium styracifolium, 5~15 parts of giant knotweed, 5~15 parts of radix cyathulae, 10~30 parts of the dried rhizome of rehmannia, wide seed of cowherb shell 3~9
Part, 5~15 parts of rhizoma atractylodis, 10~30 parts of plantain seed, 3~9 parts of golden cypress, 8~18 parts of the Radix Astragali, 5~15 parts of caulis trachelospermi, rhizoma cibotii 5~15
Part.
2. Chinese medicine composition as claimed in claim 1, it is characterised in that the weight proportion of the Chinese medicine material is：
30 parts of Desmodium styracifolium, 9 parts of giant knotweed, 9 parts of radix cyathulae, 20 parts of the dried rhizome of rehmannia, 6 parts of wide seed of cowherb shell, 9 parts of rhizoma atractylodis,
20 parts of plantain seed, 6 parts of golden cypress, 12 parts of the Radix Astragali, 9 parts of caulis trachelospermi, 9 parts of rhizoma cibotii.
3. the preparation method of Chinese medicine composition as claimed in claim 1, it is characterised in that it comprises the following steps：
Each bulk drug is taken to mix, decocting 2~3 times, add water 4~20 times of amounts every time, 1~3 hour every time, is by decocting liquid filtration merging
.
4. Chinese medicine composition as claimed in claim 1 is preparing the application in preventing and treating the medicine or health products of hyperuricemia.
5. Chinese medicine composition as claimed in claim 1 is preparing the application in preventing and treating the medicine or health products of urarthritis.
6. application of the Chinese medicine composition as claimed in claim 1 in the medicine or health products with analgesic activity is prepared.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610247818.2A CN107303330A (en) | 2016-04-20 | 2016-04-20 | One kind prevents antipodagric Chinese medicine composition and preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610247818.2A CN107303330A (en) | 2016-04-20 | 2016-04-20 | One kind prevents antipodagric Chinese medicine composition and preparation method and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107303330A true CN107303330A (en) | 2017-10-31 |
Family
ID=60151837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610247818.2A Withdrawn CN107303330A (en) | 2016-04-20 | 2016-04-20 | One kind prevents antipodagric Chinese medicine composition and preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107303330A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110433226A (en) * | 2019-08-13 | 2019-11-12 | 江阴持一堂医药科技有限公司 | A kind of Chinese medicine composition and preparation and its preparation method and application for treating urarthritis or hyperuricemia |
-
2016
- 2016-04-20 CN CN201610247818.2A patent/CN107303330A/en not_active Withdrawn
Non-Patent Citations (7)
| Title |
|---|
| 《健康大讲堂》编委会: "《痛风怎么吃》", 30 September 2015, 黑龙江科学技术出版社 * |
| 侯天印等: "《痛风偏验方与食疗》", 31 October 2013, 金盾出版社 * |
| 吴安康等: "舒筋活血片对酵母致高尿酸血症小鼠血清UA和XOD的影响", 《现代中医药》 * |
| 吴文斌: "五味消毒饮临床应用体会", 《江西中医药》 * |
| 廖勇敢等: "《内科基础与临床诊疗》", 28 February 2014, 科学技术文献出版社 * |
| 郭剑华: "痛风性关节炎", 《家庭医药》 * |
| 霍英: "《头痛眩晕奇效良方》", 31 May 2006, 人民军医出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110433226A (en) * | 2019-08-13 | 2019-11-12 | 江阴持一堂医药科技有限公司 | A kind of Chinese medicine composition and preparation and its preparation method and application for treating urarthritis or hyperuricemia |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103520497B (en) | Chinese medicinal composition for treating gout and preparation method thereof | |
| CN102058673A (en) | Chinese medicine composition for expelling wind and removing dampness and preparation method thereof | |
| CN104689173B (en) | A kind of compound Chinese medicinal preparation for treating gout | |
| CN103877438B (en) | Traditional Chinese medicine preparation for treating gout and production method thereof | |
| CN104042720B (en) | There is the Chinese medicine and application thereof of preventing and treating diabetes complicated depression | |
| CN104352901A (en) | Traditional Chinese medicine for treating gout | |
| CN107468768A (en) | A kind of Qiang's drug composition and application thereof | |
| CN104258051B (en) | Traditional Chinese medicine composition for treating gouty arthritis, and preparation method thereof | |
| CN100355450C (en) | Qinchuan Tongbi tablet | |
| CN106039109A (en) | Traditional Chinese medicinal liquor for preventing and treating cold dampness accumulation pattern rheumatoid arthritis | |
| CN105287748A (en) | Traditional Chinese medicine preparation for treating hyperuricemia and preparation method thereof | |
| CN107303330A (en) | One kind prevents antipodagric Chinese medicine composition and preparation method and application | |
| CN105194460A (en) | Traditional Chinese medicine preparation for treating acute episode stage of wind-damp-heat type gout | |
| CN102293928A (en) | Chinese medicinal composition for treating hyperuricemia and urarthritis, and preparation method and application thereof | |
| CN103908603B (en) | A kind of Chinese medicine composition treating gout and preparation method thereof | |
| CN104435314B (en) | A kind of pharmaceutical composition for treating osteoarthropathy and its application | |
| CN101884664B (en) | Medicinal composition for preventing and treating rheumatoid arthritis and preparation method thereof | |
| CN104940749A (en) | Traditional Chinese medicine composition for treating gout and preparation method | |
| CN105362798A (en) | Traditional Chinese medicine for treating gouty arthritis and preparation method of traditional Chinese medicine | |
| CN100333758C (en) | Gout resisting Chinese medicine composition and its prepn process | |
| CN105079708A (en) | Traditional Chinese medicine for treating hyperlipemia and preparation method of traditional Chinese medicine | |
| CN102755598B (en) | Medicine for treating acute gouty arthritis and preparation method thereof | |
| CN102335304B (en) | Chinese medicine composition for dispelling wind, removing dampness, invigorating blood circulation, and relieving pain and preparation method thereof | |
| CN103156940B (en) | A kind of extracting technique of Chinese medicine for garden balsam stem pain-relieving | |
| CN105617161A (en) | Traditional Chinese medicine composition for treating gout |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20171031 |
|
| WW01 | Invention patent application withdrawn after publication |